Small dense LDL: Risk factor for coronary artery disease (CAD) and its therapeutic modulation

Indian Journal of Biochemistry and Biophysics

Volumn 49, Issue 2, 2012, Pages 77-85

  Sharma, Suman B ^a   Garg, Seema ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Coronary artery disease; Dietary modulation; Drug therapy; Hypertriglyceridemia; Life style modification; sd LDL

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CLINICAL CHEMISTRY; CORONARY ARTERY DISEASE; HUMAN; METABOLISM; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CHOLESTEROL, LDL; CLINICAL CHEMISTRY TESTS; CORONARY ARTERY DISEASE; HUMANS; RISK FACTORS;

EID: 84924289816     PISSN: 03011208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Global Atlas on Cardiovascular Disease Prevention and Control (2011), pp 2-7, World Health Organization, Geneva
2. Reddy KS & Yusuf S (1993) Emerging epidemic of cardiovascular disease in developing countries. Circulation 87, 152-156
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation Treatment of high blood cholesterol in adults (Adult Treatment Panel III). (2001) JAMA 285, 2486-2497
4. Pyorala M, Miettinen H, Laakso M & Pyorala K (1998) Hyperinsulinemia predicts coronary heart disease risk in healthy middle aged men: the 22 year follow up results of the Helsinski Policeman Study. Circulation 98, 398-404
5. Sharma SB, Dwivedi S, Prabhu KM, Singh G, Kumar N & Lal MK (2005) Coronary risk variables in young asymptomatic smokers. Indian J Med Res 122, 205-210
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH & Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. N Engl J Med 333, 1301-1307
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). (1994) Lancet 344, 1383-1389
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). N Engl J Med 339, 1349-1357
9. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. (2002) Lancet 360, 7-22
10. Sharma SB, Garg S, Veerwal A & Dwivedi S (2008) hs-CRP and oxidative stress in young CAD patients: a pilot study. Indian J Clin Biochem 23, 334-336
11. Espliguero RA, Avanzas P, Sales JC, Aldama G, Pizzi C & Kaski JC (2004) C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25, 401-408
12. Kip KE, Marroquin OC & Shaw LJ (2005) Global inflammation predicts cardiovascular risk in women: A report from the Women's Ischaemia Syndrome Evaluation (WISE) study. Am Heart J 150, 900-905
13. Hokanson JE & Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3, 213-219
14. März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Bohm BO & Winkelmann BR (2004) Low-Density Lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: The Ludwigshafen risk and cardiovascular health study. Circulation 110, 3068-3074
15. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, Mcqueen M, Budaj A, Pais P, Varigos J & Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the interheart study): case-control study. Lancet 364, 937-952
16. Sniderman AD, Vu H & Cianflone K (1991) The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 89, 109-116
17. Després JP (2006) Is visceral obesity the cause of the metabolic syndrome?. Ann Med 38, 52-63
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002). Circulation 106, 3143-3421
19. Carr MC & Brunzell JD (2004) Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89, 2601-2607
20. Llurba E, Casals E, Domínguez C, Delgado J, Mercadé I, Crispi F, Martín-Gallán P, Cabero L & Gratacós E (2005) Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in pre-eclampsia. Metabolism 54, 1504-1509
21. Swinkels DW, Hak-Lemmers HL & Demacker (1987) Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res 28, 1233-1239
22. Krauss RM & Blanche PJ (1992) Detection and quantification of LDL subfractions. Curr Opin Lipidol 3, 377-383
23. Otvos JD, Jeyarajah EJ, Bennett DW & Krauss RM (1992) Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38, 1632-1638
24. Berneis KK & Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43, 1363-1379
25. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, Castelli WP & Schaefer EJ (1992) Low density lipoprotein particle size distribution: results from the Framingham Offspring Study. Arterioscler Thromb 12,1410-1419
26. Krauss R & Burke D (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23, 97-104
27. Austin M, Breslow J, Hennekens C, Buring J, Willett W & Krauss R (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260, 1917-1921
28. Berneis K & Rizzo M (2004) LDL size: does it matter? Swiss Med Week 134, 720-724
29. Rizzo M & Berneis K (2006) Should we measure routinely the LDL peak particle size? Int J Cardiol 107, 166-170
30. Ayyobi AF; McGladdery SH, McNeely MJ, Austin MA, Motulsky AG & Brunzell JD (2003) Small dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23, 1289-1294
31. Bossé Y, Vohl MC, Despres JP, Lamarche B, Rice T, Rao DC, Bouchard C & Perusse L (2003) Heritability of LDL peak particle diameter in the Quebec Family Study. Genet Epidemiol 25, 375-381
32. Vakkilainen J, Pajukanta P, Cantor RM, Nuotio IO, Lahdenpera S, Ylitalo K, Pihlajamaki J, Kovanen PT, Laakso M, Viikari JS, Peltonen L & Taskinen MR (2002) Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. Eur J Hum Genet 10, 547-552
33. Rizzo M, Barbagallo CM, Severino M, Polizzi F, Onorato F, Noto, Cefalu AB, Pace A, Marino G, Notarbartolo A & Averna RM (2003) Low-density-lipoprotein peak particle size in a Mediterranean population. Eur J Clin Invest 33, 126-133
34. de Graaf J, Swinkels DW, Demacker PN, de Haan AF & Stalenhoef AF (1993) Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls. J Clin Endocrinol Metab 76, 197-202
35. Dreon DM, Fernstrom HA, Williams PT & Krauss RM (1997) LDL subclass patterns and lipoprotein response to a low-fat, high-carbohydrate diet in women. Arterioscler Thromb Vasc Biol 17, 707-714
36. Naganuma R, Sakurai M, Miura K, Yoshita K, Morikawa Y, Kido T, Ueshima H, Nakagawa H & Stamler J (2009) Relation of long-term body weight change to change in lipoprotein particle size in Japanese men and women: the INTERMAP Toyama Study. Atherosclerosis 206, 282-286
37. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ & Shepherd J (1994) Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small dense LDL to coronary heart disease risk. Atherosclerosis 6, 241-253
38. Tan CE, Forster L, Caslake MJ, Bedford D, Watson TDG, McConnell M, Packard CJ & Shepherd J (1995) Relations between plasma lipids and post heparin plasma lipases and VLDL and LDL subfractions in normolipemic men and women. Arterioscler Thromb Vasc Biol 15, 1839-1848
39. Capell WH, Zambon A, Austin MA, Brunzell JD & Hokanson JE (1996) Compositional Differences of LDL Particles in Normal Subjects With LDL Subclass Phenotype A and LDL Subclass Phenotype B. Arterioscler Thromb Vasc Biol 16, 1040-1046
40. Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R & Thornalley P J (2011) Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60, 1973-1980
41. Dejager S, Bruckert E & Chapman MJ (1993) Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 34, 295-308
42. Tribble DL, Holl LG, Wood PD & Krauss RM (1992) Variations in oxidative susceptibility among six low density subfractions of differing density and particle size. Arteriosclerosis 93, 189-199
43. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F & Collen D (1998) Oxidized LDL and malondialdehydemodified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98, 1487-1494
44. Chang CJ, Hsieh RH, Wang HF, Chin MY & Huang SY (2005) Effects of glucose and alpha-tocopherol on lowdensity lipoprotein oxidation and glycation. Ann N Y Acad Sci 1042, 294-302
45. Scheffer PG, Teerlink T & Heine RJ (2005) Clinical significance of the physicochemical properties of LDL in type 2 diabetes. Diabetologia 48, 808-816
46. Galeano NF, Milne R, Marcel YL, Walsh MT, Levy E, Ngu'yen T, Gleeson A, Arad Y, Witte L, Al-Haideri M, Rumsey SC & Deckelbaum RJ (1994) Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269, 511-519
47. Liu M, Krul ES & Subbaiah PV (1992) Effect of apoprotein B conformation on the activation of lipolecithin acyltransferase and lecithin:cholesterol acyltransferase. J Biol Chem 267, 5139-5147
48. McKeone BJ, Patsch JR & Pownall HJ (1993) Plasma triglycerides determine low density lipoprotein composition, physical properties and cell-specific binding in cultured cells. J Clin Invest 91, 1926-1933
49. Soran H, Durrington PN (2011) Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 22, 254-261
50. Halle M, Berg A, Keul J & Baumstark M W (1996) Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 16, 144-148
51. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie P D & Szklo M (1991) Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91, 191-205
52. Väisänen S, Baumstark MW, Penttilä I, Bouchard C, Halonen P, Rankinen T Berg A & Rauramaa R (1997) Small dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost 78, 1495-1499
53. Festa A, D'Agostino R Jr, Mykkänen L, Tracy R, Howard BV & Haffner SM (1999) Low-Density Lipoprotein Particle Size Is Inversely Related to Plasminogen Activator Inhibitor-1 Levels; The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 19, 605-610
54. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H & Juhan-Vague I (1991) Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 11, 1821-1829
55. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M & Yasue H (1993) Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73, 335-343
56. Shimabukuro M, Higa N, Asahi T, Oshiro Y & Takasu N (2004) Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction. Metabolism 53, 733-739
57. Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A, Vehkavaara S, Lahdenperä S, Groop PH, Taskinen MR & Yki-Järvinen H (2000) Endothelial dysfunction in men with small LDL particles. Circulation 102, 716-721
58. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Luben R, Kastelein JJP, Khaw KT & Boekholdt SM (2007) Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J 28, 2770-2777
59. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD & Sharp DS (2000) Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 86, 412-416
60. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ & Després JP (1997) Small, dense lowdensity lipoprotein particles as a predictor of the risk of ischemic heart disease in men Prospective results from the Québec Cardiovascular Study. Circulation 95, 69-75
61. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM & Hennekens CH (1996) A prospective study of triglyceride level, low-density lipoprotein particle diameter; and risk of myocardial infarction. JAMA 276, 882-888
62. Maeda S, Nakanishi S, Yoneda M, Awaya T, Yamane K, Hirano T, Kohno N (2011) Association between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. J Athero Thromb 18 [Epub ahead of print]
63. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP & Lamarche B (2005) Low-Density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25, 553-559
64. Erdman JW Jr (2000) Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 102, 2555-2559
65. Clarkson TB (2002) Soy, soy phytoestrogens and cardiovascular disease. J Nutr 132, 566S-569S
66. van Ee JH (2009) Soy constituents: modes of action in low-density lipoprotein management. Nutr Rev 67, 222-234
67. Marchioli R, Schweiger C, Levantesi G, Tavazzi L & Valagussa F (2001) Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36, 53S-63S
68. Yusuf S, Dagenais G, Pogue J, Bosch J & Sleight P (2000) Vitamin E supplementation and cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342, 154-160
69. Decewicz DJ, Neatrour DM, Burke A, Haberkorn MJ, Patney HL, Vernalis MN & Ellsworth DL (2009) Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis 8, 26
70. Utarwuthipong T, Komindr S, Pakpeankitvatana V, Songchitsomboon S & Thongmuang N (2009) Small dense low-density lipoprotein concentration and oxidative susceptibility changes after consumption of soybean oil, rice bran oil, palm oil and mixed rice bran/palm oil in hypercholesterolaemic women. J Int Med Res 37, 96-104
71. Marais AD (2000) Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol 11, 597-602
72. Otvos JD, Shalaurova I, Freedman DS & Rosenson RS (2002) Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 160, 41-48
73. Kontopoulos AG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC & Boudoulas H (1996) Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 7, 843-850
74. März W, Scharnagl J, Abletshauser C, Hoffman MM, Berg A, Keul J, Wieland H & Baumstark MW (2001) Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with atherogenic lipoprotein phenotype. Circulation 103, 1942-1948
75. McKenney JM, McCormick LS, Schaefer EJ, Black DM & Watkins ML (2001) Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88, 270-274
76. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ & Caslake MJ (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164, 129-145
77. Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ & Heine RJ (2000) Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 16, 82-87
78. Shimabukuro M, Higa N, Asahi T, Oshiro Y & Takasu N (2004) Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction Metabolism 53, 733-739
79. Barbier O, Pineda Torra I, Duguay Y, Blanquart C, Fruchart JC, Glineur C & Staels B (2002) Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22, 717-726
80. Stalenhoef AF, deGraaf J, Wittekoek ME, Bredie SJ, Demacker PN & Kastelein JJ (2000) The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 153, 129-138
81. Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J & Després JP (2002) A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162, 363-371
82. Schweitzer M, Tessie D, Vlahos WD, Leiter L, Collet JP, McQueen MJ, Harvey L, Alaupovic P (2002) A comparison of pravastatin and gemfibrozil in the treatment of dyslipoprotein in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 162, 201-210
83. Frost JA, Otto C, Geiss C, Schwandt P & Parhofer KG (2001) Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87, 44-48
84. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB & Rademaker AW (2007) Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30, 1945-1951
85. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE & Robins SJ (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113, 1556-1563
86. Hokanson JE, Austin MA, Zambon A & Brunzell JD (1993) Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 13, 427-434
87. Tavintharan S & Kashyap ML (2001) The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 3, 74-82
88. Knopp RH (2002) Evaluating niacin in its various forms. Am J Cardiol 86 (Suppl), 51L-56L
89. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich Jr PO, Harper WL, Toth PDS, Favrot LK, Kerzner B, Nash SD, Bays HE & Simmons PD (2002) Longterm safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89, 672-678
90. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B & Veltri EP (2002) Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90, 1092-1097
91. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA & Gumbiner B (2002) Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90, 1084-1091
92. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S & Veltri EP (2002) Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40, 2125-2134
93. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A (2009) Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, threeparallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 9, 91-101
94. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R & Martin J (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24, 378-396
95. Khan MA, St Peter JV & Xue JL (2002) A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25, 708-711
96. Hanefeld M (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes Obes Metab 11, 742-756
97. Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, Lübben G & Hanefeld M (2008) Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis 201, 155-162